Expesicor, Novoron Bioscience to collaborate on treatment for central nervous system disorders

Written by Alan Condon | April 25, 2019 | Print  |

A Montana therapeutic drug developer and California biotech company have agreed to collaborate on novel approaches for treating disorders of the central nervous system.

Last year, Kalispell, Mont.-based Expesicor and Novoron Bioscience of San Diego began working together on a compound for the treatment of neurodegenerative disorders like Alzheimer's disease. They've since co-developed a compound that is in preclinical testing.

Expesicor has considerable experience in drug development for neurological disorders and has developed proprietary therapeutics, imaging probes and drug-screening tools for epilepsy, neurodegenerative disorders, depression, autism and other brain disorders.

Novoron has implemented a novel approach to restoring the regenerative capacity of the brain and spinal cord, and is advancing its channel of biologic therapeutics for the treatment of multiple sclerosis and spinal cord injury.

More articles on biologics:
4 benefits of stem cells in orthopedics from Dr. Jeffrey Carroll
4 trends in spinal fusion market growth, to reach $58.2B by 2025
Spinal fusion costs associated with staph infection: 5 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months